本实验旨在探讨五味苦参肠溶胶囊对溃疡性结肠炎模型小鼠miR-21及炎症因子IL-6表达的影响,并探究其在治疗UC中可能的作用机制.溃疡性结肠炎近年来随着生活习惯的不断改变,发病率逐年增高,根治溃疡性结肠炎依然是目前医疗界赤手可热的话题,传统的治疗方案仍不能给患者带来良好的预后,探究新型方式治疗溃疡性结肠炎的研究具有广阔的前景,本文就溃疡性结肠炎治疗的最新进展做简要综述.

目的:通过对骨髓单个核细胞(BM-MNCs)移植治疗溃疡性结肠炎(UC)小鼠模型中miR-155的表达,探讨BM-MNCs移植对UC的疗效及作用机制.方法:72只小鼠取54只随机分为正常对照组、UC模型组、BM-MNCs移植组,对UC模型组和BM-MNCs移植组构建小鼠溃疡性结肠炎模型,余18只小鼠用于提取BM-MNCs,对成功构建UC模型的移植组小鼠进行BM-MNCs细胞移植,对移植前后的各组小鼠使用DAI评分,HE染色的方法观察肠道组织损伤情况,应用rt-PCR技术测结肠组织中miR-155的表达.结果:BM-MNCs移植组中,移植后小鼠结肠组织中miR-155的表达较UC模型明显降低,且DAI评分随之降低,与UC模型组相比差异有统计学意义(P＜0.05).结论:BM-MNCs移植对小鼠UC有治疗作用,并且考虑其通过抑制miR-155及其相关因子的表达而发挥效应.

目的 ;对依那普利和氨氯地平联合运用于高血压临床治疗的疗效进行观察.方法:分析高血压病人(86例)临床症状,随机均等分为实验组(氨氯地平联合依那普利)和对照组(氨氯地平),进行组间样本病例治疗疗效比较.结果:对照组、实验组样本病例血压控制效果都有所好转,两组总有效率分别为88.3％、97.6％,组间差异明显,P＜0.05.结论:选择运行依那普利+氨氯地平联合方案治疗高血压病人的临床效果比较理想,临床意义突出.

目的:酒精性肝硬化的临床治疗实践中还原型谷胱甘肽的应用疗效观察.方法:将酒精性肝硬化病人(68例)样本从入院治疗者中随机选出并进行组别划分,具体均分成2组,即观察组与观察组,前者给予常规治疗,后者采用还原型谷胱甘肽+常规治疗组合策略.结果:观察组总有效率超过对照组,观察组与观察组的组间差异显著,有统计学意义(P＜0.05).结论:还原型谷胱甘肽可以有效治疗酒精性肝硬化病人,可以在临床中普遍应用.

头帕肿瘤综合征蛋白因具有肿瘤抑制因子的作用而被广泛研究.圆柱瘤病基因CYLD编码的活性蛋白是一种细胞内多功能去泛素化酶,能去除特定底物的RIP1、TRAFs、NEMO和Bcl-3等信号分子及K63泛素链[1],可抑制多聚泛素依赖性信号通路,包括促炎和促进细胞生长的NF-KB通路、JNK等信号通路[2].从而参与了促炎反应、恶性细胞增殖与分化、细胞凋亡等,在肿瘤发生发展过程中发挥抑癌基因的作用.

Objective: To investigate the effect of bone marrow mononuclear cell transplantation on the expression of miRNA-21 and miRNA-155 in mice with ulcerative colitis(UC). Methods: Healthy and clean KM mice aged 6-8 weeks were randomly divided into transplantation group, model group and normal control group with 15 mice in each group. In the transplantation group and model group, dextran sodium sulfate (DSS) was used to establish the model for 24 h. The mice in the transplantation group were injected with 0.4 ml of 4 ', 6-diaminol-2-phenylindole (DAPI) -labeled P3-BM-MNCs cell suspension (3.2×10(6) cells/ml), and the mice in the model group and the normal control group were injected with 0.4 ml phosphate buffer (PBS).UC disease activity index (DAI) was used to test the general condition of mice; HE staining was used to observe the pathological changes of colon tissue; Real-time quantitative PCR was used to detect the expression of miRNA-21 and miRNA-155 mRNA. Results: DAI scores of normal control group, model group and transplantation group were 0 (0,1), 3.1 (2.8,3.3) and 2.7 (2.4,3.1),respectively. Compared with normal control group, the DAI score of model group and transplantation group was higher (P<0.05), and the DAI score of transplantation group was lower than that of model group (P<0.05). The gross scores of tissue injury in normal control group, model group and transplantation group were 0 (0, 1), 3 (3, 4) and 1 (1, 2), respectively,and the pathological scores of tissue injury were 0 (0, 1), 16 (12, 16) and 6 (6, 8), respectively,compared with the normal control group. The tissue injury score of the model group and the transplantation group was higher (P<0.05), and the tissue injury score of the transplantation group was lower than that of the model group (P<0.05). The expression levels of miRNA-21 mRNA in normal control group, model group and transplantation group were 0.87±0.15, 2.38±0.29 and 1.59±0.32, respectively, and the expression levels of miRNA-155 mRNA were 1.87±0.46, 7.38±1.97 and 3.92±0.84, respectively, compared with the normal control group, the expression of miRNA-21 and miRNA-155 mRNA in the model group and transplantation group was higher (P<0.01), the expression of miRNA-21 and miRNA-155 mRNA in the transplantation group was lower than that of the model group (P<0.05). Conclusion: Bone marrow mononuclear cell transplantation can improve the histopathological and DAI scores of mice with UC, which may be related to the down-regulation of miRNA-21 and miRNA-155 mRNA expression.

目的:探讨荆花胃康联合三联疗法在Hp(幽门螺杆菌)感染患者中的临床观察.方法:选取佳木斯大学附属第一医院收治的136例幽门螺杆菌感染慢性胃炎患者作为研究对象,随机分为两组,实验组68侧,对照组68例.实验组及对照组均服用雷贝拉唑,阿莫西林,克拉霉素传统的三联疗法,实验组该基础上加上荆花胃康进行治疗.对照维联合应用用安慰剂治疗,两组患者均连续服药时间为4周.治疗结束后停药,1个月后复查14C呼气试验.观察比较、幽门螺杆菌清除率、临床总有效率及、消化道症状,治疗期间药物不良反应率,结果:比较两组患者.治疗后实验组的幽门螺杆菌清除率明显高于对照组(P＜0.05),总有效率实验组为96％,对照组为84％,2组比较,差异有统计学意义(P＜0.05).实验组与对照组患者腹胀、上腹痛、纳差、暖气等消化道症状评分均较治疗前明显降低(P＜0.05),并且实验组各项症状评分均低于对照组(P＜0.05).两组患者在服药治疗过程中都未发生严重的不良反应,一般不良反应率比较差异无统计学意义(P＞0.05).结论:荆花胃康联合传统三联疗法治疗幽门螺杆菌所感染的慢性胃炎患者,可以显著提升临床总有效率,降低临床消化道症状率,药效发挥迅速,不良反应少,提高临床疗效,提升患者生活质量.